Large-scale prevention trials could provide stronger evidence for decision-makers: Opportunities to design and report with a focus on the benefit

Large-scale prevention trials could provide stronger evidence for decision-makers: Opportunities to design and report with a focus on the benefit–harm balance

Published:2022-02-13 Issue:2 Volume:19 Page:224-226
ISSN:1740-7745
Container-title:Clinical Trials
language:en
Short-container-title:Clinical Trials

Author:

Aschmann Hélène E¹²^ORCID,McNeil John J³,Puhan Milo A¹⁴

Affiliation:

1. Epidemiology, Biostatistics and Prevention Institute, Department of Epidemiology, University of Zurich, Zurich, Switzerland

2. Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, USA

3. School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia

4. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Funder

béatrice ederer-weber stiftung

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Publisher

SAGE Publications

Subject

Pharmacology,General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/17407745211068549

Reference12 articles.

1. Practical help for specifying the target difference in sample size calculations for RCTs: the DELTA2 five-stage study, including a workshop

2. A Randomized Trial of Intensive versus Standard Blood-Pressure Control

3. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary

4. Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians

5. Effect of Aspirin on Disability-free Survival in the Healthy Elderly

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living bene fi t - harm modelling study;ECLINICALMEDICINE;2024

2. GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit–harm modelling study;eClinicalMedicine;2024-07

3. Fingolimod versus interferon beta 1-a: Benefit–harm assessment approach based on TRANSFORMS individual patient data;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2022-07